SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001347178-18-000007
Filing Date
2018-08-02
Accepted
2018-08-02 07:01:11
Documents
80
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q vnda0630201810q.htm 10-Q 994108
2 EX-31.1 vndaex31106302018.htm EX-31.1 13564
3 EX-31.2 vndaex31206302018.htm EX-31.2 13532
4 EX-32.1 vndaex32106302018.htm EX-32.1 9458
  Complete submission text file 0001347178-18-000007.txt   5648663

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT vnda-20180630.xml EX-101.INS 1073131
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20180630.xsd EX-101.SCH 55035
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20180630_cal.xml EX-101.CAL 99276
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20180630_def.xml EX-101.DEF 217208
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20180630_lab.xml EX-101.LAB 633193
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20180630_pre.xml EX-101.PRE 384221
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 18986603
SIC: 2834 Pharmaceutical Preparations